Test Price
2,800 AED✅ Home Collection Available
CRB2 Gene Focal Segmental Glomerulosclerosis Type 9 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via Next‑Generation Sequencing (NGS) processed in our ISO‑accredited genomics laboratory. Every run includes Sanger confirmation of pathogenic variants.
Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. Strict ISO‑certified transport for whole blood, extracted DNA, or FTA card samples.
Clinical Guidance: Telephonic post‑test clinical interpretation session with a DHA‑licensed genetic counsellor included. You receive actionable insights on treatment implications and cascade screening.
Insurance & Payment: Direct billing verification via WhatsApp (+971 54 548 8731). We handle pre‑approvals with all UAE insurers.
This single‑gene analysis provides definitive molecular confirmation for families affected by steroid‑resistant nephrotic syndrome, enabling precise prognosis and informed family planning.
Test Overview & Methodology
Comprehensive CRB2 Gene Analysis for Hereditary Nephrotic Syndrome
This single‑gene next‑generation sequencing test screens the entire coding region of CRB2—the gene responsible for focal segmental glomerulosclerosis type 9 (FSGS 9). Inherited in an autosomal recessive pattern, pathogenic variants lead to steroid‑resistant nephrotic syndrome, often progressing to end‑stage renal disease in childhood or early adulthood. In the UAE, where consanguinity rates may elevate recessive disease burden, this test provides families and clinicians with definitive molecular confirmation, enabling precise prognosis, tailored immunosuppressive strategies, and informed family planning.
| Feature | Our Test (CRB2 NGS) | Conventional Sanger Sequencing |
|---|---|---|
| Methodology | NGS (Next‑Generation Sequencing) with Sanger validation | Sanger sequencing of individual exons |
| Turnaround Time | 3–4 weeks | 6–8 weeks for full gene |
| Coverage | Complete coding region ± flanking splice sites – detects SNVs, indels, and CNVs | Targeted exon analysis only; large deletions/duplications often missed |
| Clinical Utility | Confirms FSGS 9 diagnosis, guides family screening, and informs transplant eligibility | Partial gene sequencing; less informative for recessive inheritance patterns |
| Price (AED) | 2800 | Variable |
Physician Insight & Safety Protocols
"A positive CRB2 result must be interpreted within the full clinical picture; isolated genetic data does not dictate therapy. However, it empowers your nephrologist to refine immunosuppressive regimens, accelerates transplant readiness, and enables cascade testing of at‑risk siblings. As a consultant in medical genetics, I always emphasize that this test is a starting point for a lifelong, family‑centered care plan."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory & Safety Considerations
⚠️ Clinical Advisory
Do not discontinue or modify any prescribed medication (e.g., steroids, immunosuppressants, antihypertensives) based solely on this genetic result. Always consult your treating physician.
- ER red flags: Rapidly progressing edema, oliguria/anuria, uncontrolled hypertension, or sudden drop in urine output demand immediate emergency care – do not wait for genetic results.
- Pre‑test requirement: A detailed clinical history and a three‑generation pedigree chart, preferably drawn with a genetic counsellor, must accompany the sample to maximize interpretive accuracy.
Exclusion Criteria
Inability to provide an adequate biological sample (blood, DNA, or FTA card); suspected acute kidney injury requiring urgent intervention. Individuals with known hypersensitivity to standard phlebotomy procedures may require alternative sampling arrangements.
Patient FAQ & Clinical Guidance
1. What is the CRB2 gene test and why is it ordered?
Answer: The CRB2 NGS test identifies disease‑causing variants in the CRB2 gene that lead to steroid‑resistant nephrotic syndrome (FSGS type 9), enabling definitive diagnosis and targeted family screening.
2. How is the sample collected and can it be done at home?
Answer: A small volume of whole blood, extracted DNA, or a finger‑prick blood spot on an FTA card is collected. We offer VIP mobile phlebotomy with temperature-controlled cold-chain home collection across all Emirates, available daily from 8 AM to 11 PM.
3. What will the results tell my doctor and what happens next?
Answer: Results classify variants as pathogenic, likely pathogenic, or variants of uncertain significance, guiding kidney biopsy interpretation, transplant evaluation, and carrier testing for relatives.
4. How long does it take to get results?
Answer: The standard turnaround time is 3–4 weeks from sample receipt. This includes NGS sequencing, bioinformatics analysis, Sanger confirmation of any detected variants, and clinical report generation.
5. Is genetic counselling available after the test?
Answer: Yes, a telephonic post‑test clinical interpretation session with a DHA‑licensed genetic counsellor is included. This session helps you understand the implications for treatment, surveillance, and family planning.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance Framework
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is de‑identified and stored in encrypted, DHA‑approved servers. Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory accredited to ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). DHA Facility License Number: 1143.
Clinical & Logistical Metadata
| Test Name | CRB2 Gene Focal Segmental Glomerulosclerosis Type 9 Genetic Test (NGS with Sanger Validation) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or FTA card blood spot. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation of all pathogenic variants |
| ICD-10-CM Code | N04.9 (Nephrotic syndrome with unspecified morphologic changes), N04.1 (Nephrotic syndrome with focal and segmental glomerular lesions) |
| LOINC Code | 101381-1 (CRB2 gene targeted mutation analysis in blood or tissue by NGS) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians